Glucagon Manufacturing in PLI Scheme | 01 Jul 2024

Recently, the government decided to manufacture a Glucagon-like peptide receptor agonist (GLP-1RA) drug in India under the Production Linked Incentive (PLI) scheme from 2026.
GLP-1RA is a class of anti-diabetic drugs which are also used for weight loss.
Apart from GLP-1RA, investors are planning to make other drugs like Ozempic (for diabetes), and Wegovy (for obesity) at the site and the PLI scheme will provide manufacturing avenues in India.
The PLI scheme is an ambitious central scheme to scale up domestic manufacturing capability, accompanied by higher import substitution and employment generation.
Launched in March 2020, the scheme at present covers 14 sectors.
Under the scheme, Domestic and Foreign companies receive financial rewards for manufacturing in India, based on a percentage of their revenue over up to five years.